{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:08:49Z","timestamp":1791446929407,"version":"4.3.3"},"reference-count":153,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000860","name":"European Society of Cardiology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000860","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000860","name":"European Society of Cardiology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000860","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Advances in cancer treatments have improved clinical outcomes, leading to an increasing population of cancer survivors. However, this success is associated with high rates of short- and long-term cardiovascular (CV) toxicities. The number and variety of cancer drugs and CV toxicity types make long-term care a complex undertaking. This requires a multidisciplinary approach that includes expertise in oncology, cardiology and other related specialties, and has led to the development of the cardio-oncology subspecialty.<\/jats:p>\n                  <jats:p>This paper aims to provide an overview of the main adverse events, risk assessment and risk mitigation strategies, early diagnosis, medical and complementary strategies for prevention and management, and long-term follow-up strategies for patients at risk of cancer therapy-related cardiotoxicities. Research to better define strategies for early identification, follow-up and management is highly necessary. Although the academic cardio-oncology community may be the best vehicle to foster awareness and research in this field, additional stakeholders (industry, government agencies and patient organizations) must be involved to facilitate cross-discipline interactions and help in the design and funding of cardio-oncology trials.<\/jats:p>\n                  <jats:p>The overarching goals of cardio-oncology are to assist clinicians in providing optimal care for patients with cancer and cancer survivors, to provide insight into future areas of research and to search for collaborations with industry, funding bodies and patient advocates. However, many unmet needs remain. This document is the product of brainstorming presentations and active discussions held at the Cardiovascular Round Table workshop organized in January 2020 by the European Society of Cardiology.<\/jats:p>","DOI":"10.1002\/ejhf.1985","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T07:28:24Z","timestamp":1598599704000},"page":"2290-2309","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":127,"title":["The Cancer Patient and Cardiology"],"prefix":"10.1093","volume":"22","author":[{"given":"Jos\u00e9 Luis","family":"Zamorano","sequence":"first","affiliation":[{"name":"Department of Cardiology, University Hospital Ram\u00f3n y Cajal, CiberCV , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"Gottfridsson","sequence":"additional","affiliation":[{"name":"Cardiovascular Safety Centre of Excellence, Patient Safety, CMO Organization, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Asteggiano","sequence":"additional","affiliation":[{"name":"ESC Council of Cardio-Oncology, Insubria University of Medicine , Varese ,","place":["Italy"]},{"name":"LARC (Laboratorio Analisi Ricerca Clinica) , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Atar","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Ulleval , Oslo ,","place":["Norway"]},{"name":"Institute of Clinical Sciences, University of Oslo , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Badimon","sequence":"additional","affiliation":[{"name":"ESC Advocacy Committee 2018\u20132020, Director Cardiovascular Programme (ICCC)-IR Hospital de la Santa Creu I Sant Pau, CiberCV , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J.","family":"Bax","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leiden University Medical Centre , Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cardinale","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Unit, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Cardone","sequence":"additional","affiliation":[{"name":"European Cancer Patient Coalition , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.M.","family":"Feijen","sequence":"additional","affiliation":[{"name":"Princess Maxima Centre for Paediatric Oncology , Utrecht ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Ferdinandy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, Semmelweis University , Budapest ,","place":["Hungary"]},{"name":"Pharmahungary Group , Szeged ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"L\u00f3pez-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital La Paz, IdiPAZ, Ciber CV , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris P.","family":"Gale","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Maduro","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Groningen, University Medical Centre Groningen , Groningen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid","family":"Moslehi","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Program, Vanderbilt University Medical Center , Nashville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torbj\u00f8rn","family":"Omland","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Akershus University Hospital, University of Oslo , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Plana Gomez","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Texas Heart Institute and Baylor College of Medicine , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Scott","sequence":"additional","affiliation":[{"name":"Exercise Oncology Research Program, Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Suter","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Minotti","sequence":"additional","affiliation":[{"name":"Campus Bio-Medico University School of Medicine , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,2]]},"reference":[{"key":"2026011721383875700_ejhf1985-bib-0001","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(19)30456-5","article-title":"Progress in cancer survival, mortality, and incidence in seven high-income countries 1995\u20132014 (ICBP SURVMARK-2): a population-based study","volume":"20","author":"Arnold","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0002","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ijc.31664","article-title":"Global cancer incidence in older adults, 2012 and 2035: a population-based study","volume":"144","author":"Pilleron","year":"2019","journal-title":"Int J Cancer"},{"key":"2026011721383875700_ejhf1985-bib-0003","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"2026011721383875700_ejhf1985-bib-0004","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1200\/JCO.2013.49.3205","article-title":"Modifiable risk factors and major cardiac events among adult survivors of childhood cancer","volume":"31","author":"Armstrong","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0005","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N Engl J Med"},{"key":"2026011721383875700_ejhf1985-bib-0006","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1161\/CIR.0000000000000641","article-title":"Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the American Heart Association","volume":"139","author":"Campia","year":"2019","journal-title":"Circulation"},{"key":"2026011721383875700_ejhf1985-bib-0007","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/j.seminoncol.2019.10.006","article-title":"Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology","volume":"46","author":"Yeh","year":"2019","journal-title":"Semin Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0008","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3389\/fphar.2018.01058","article-title":"Anticancer therapy-induced atrial fibrillation: electrophysiology and related mechanisms","volume":"9","author":"Yang","year":"2018","journal-title":"Front Pharmacol"},{"key":"2026011721383875700_ejhf1985-bib-0009","doi-asserted-by":"crossref","DOI":"10.1177\/1753944719843435","article-title":"Cardiotoxicity due to targeted anticancer agents: a growing challenge","volume":"13","author":"Shah","year":"2019","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"2026011721383875700_ejhf1985-bib-0010","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","article-title":"Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management","volume":"109","author":"Yeh","year":"2004","journal-title":"Circulation"},{"key":"2026011721383875700_ejhf1985-bib-0011","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"key":"2026011721383875700_ejhf1985-bib-0012","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026011721383875700_ejhf1985-bib-0013","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0014","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2026011721383875700_ejhf1985-bib-0015","doi-asserted-by":"crossref","first-page":"H1453","DOI":"10.1152\/ajpheart.00554.2015","article-title":"Drug-induced mitochondrial dysfunction and cardiotoxicity","volume":"309","author":"Varga","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026011721383875700_ejhf1985-bib-0016","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jacc.2019.07.006","article-title":"Prevention, diagnosis, and management of radiation-associated cardiac disease: JACC Scientific Expert Panel","volume":"74","author":"Desai","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026011721383875700_ejhf1985-bib-0017","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/ehjci\/jet123","article-title":"Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography","volume":"14","author":"Lancellotti","year":"2013","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026011721383875700_ejhf1985-bib-0018","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jacc.2009.10.047","article-title":"Sustained inflammation due to nuclear factor-kappa B activation in irradiated human arteries","volume":"55","author":"Halle","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026011721383875700_ejhf1985-bib-0019","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2026011721383875700_ejhf1985-bib-0020","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/eurheartj\/ehy365","article-title":"Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications","volume":"40","author":"Ferdinandy","year":"2019","journal-title":"Eur Heart J"},{"key":"2026011721383875700_ejhf1985-bib-0021","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ejhf.1165","article-title":"Heart Failure Association cardio-Oncology Study Group of the European Society of Cardiology. Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge","volume":"20","author":"Ameri","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026011721383875700_ejhf1985-bib-0022","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1001\/jamacardio.2019.0302","article-title":"Connections between clonal hematopoiesis, cardiovascular disease, and cancer: a review","volume":"4","author":"Calvillo-Arguelles","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2026011721383875700_ejhf1985-bib-0023","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"2026011721383875700_ejhf1985-bib-0024","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0025","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.seminoncol.2019.10.005","article-title":"Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology","volume":"46","author":"Breccia","year":"2019","journal-title":"Semin Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0026","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11739-015-1362-x","article-title":"Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer","volume":"11","author":"Mantarro","year":"2016","journal-title":"Intern Emerg Med"},{"key":"2026011721383875700_ejhf1985-bib-0027","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","article-title":"Genetic variants associated with cancer therapy-induced cardiomyopathy","volume":"140","author":"Garcia-Pavia","year":"2019","journal-title":"Circulation"},{"key":"2026011721383875700_ejhf1985-bib-0028","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","author":"Lyon","year":"2020  28","journal-title":"Eur J Heart Fail"},{"key":"2026011721383875700_ejhf1985-bib-0029","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/1471-2407-10-337","article-title":"Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials","volume":"10","author":"Smith","year":"2010","journal-title":"BMC Cancer"},{"key":"2026011721383875700_ejhf1985-bib-0030","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/ejhf.1168","article-title":"Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial","volume":"20","author":"Banke","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026011721383875700_ejhf1985-bib-0031","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaoncol.2018.6634","article-title":"Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity","volume":"5","author":"Feijen","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0032","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2026011721383875700_ejhf1985-bib-0033","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ejhf.1610","article-title":"Myocardial dysfunction in long-term breast cancer survivors treated at ages 40\u201350\u2009years","volume":"22","author":"Jacobse","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026011721383875700_ejhf1985-bib-0034","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","article-title":"Cardiotoxicity of anthracyclines","volume":"7","author":"Cardinale","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"2026011721383875700_ejhf1985-bib-0035","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1542\/peds.2012-0727","article-title":"Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes","volume":"130","author":"Lipshultz","year":"2012","journal-title":"Pediatrics"},{"key":"2026011721383875700_ejhf1985-bib-0036","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005006.pub3","article-title":"Different anthracycline derivates for reducing cardiotoxicity in cancer patients","author":"van Dalen","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2026011721383875700_ejhf1985-bib-0037","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaccao.2019.08.003","article-title":"Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer","volume":"1","author":"Macedo","year":"2019","journal-title":"JACC CardioOncol"},{"key":"2026011721383875700_ejhf1985-bib-0038","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"2026011721383875700_ejhf1985-bib-0039","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.2008.18.4028","article-title":"Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735","volume":"27","author":"Jones","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0040","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: a review","volume":"10","author":"Sara","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0041","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1093\/annonc\/mdx411","article-title":"DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update","volume":"28","author":"Henricks","year":"2017","journal-title":"Ann Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0042","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.bbamem.2015.01.003","article-title":"The concomitant management of cancer therapy and cardiac therapy","volume":"1848","author":"Salvatorelli","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"2026011721383875700_ejhf1985-bib-0043","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/ejhf.1385","article-title":"Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients","volume":"21","author":"Keramida","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026011721383875700_ejhf1985-bib-0044","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djaa054","article-title":"Impact of stopping trastuzumab in early breast cancer: a population-based study in Ontario, Canada","author":"Rushton","year":"2020  28","journal-title":"J Natl Cancer Inst"},{"key":"2026011721383875700_ejhf1985-bib-0045","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10549-016-3823-y","article-title":"Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study","volume":"157","author":"Gong","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2026011721383875700_ejhf1985-bib-0046","author":"European Medicines Agency. Herceptin (trastuzumab)","year":"2020"},{"key":"2026011721383875700_ejhf1985-bib-0047","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10549-019-05139-6","article-title":"Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction","volume":"175","author":"Hussain","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"2026011721383875700_ejhf1985-bib-0048","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","article-title":"Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study","volume":"175","author":"Lynce","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"2026011721383875700_ejhf1985-bib-0049","first-page":"11","volume-title":"Cancer and the Heart","author":"Salvatorelli","year":"2017","edition":"3rd edn"},{"key":"2026011721383875700_ejhf1985-bib-0050","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0051","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.critrevonc.2014.12.008","article-title":"Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"94","author":"Ghatalia","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026011721383875700_ejhf1985-bib-0052","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/bjc.2014.564","article-title":"QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"112","author":"Ghatalia","year":"2015","journal-title":"Br J Cancer"},{"key":"2026011721383875700_ejhf1985-bib-0053","author":"European Medicines Agency. Tasigna (nilotinib)","year":"2020"},{"key":"2026011721383875700_ejhf1985-bib-0054","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","article-title":"Ibrutinib-associated atrial fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"key":"2026011721383875700_ejhf1985-bib-0055","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"key":"2026011721383875700_ejhf1985-bib-0056","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"key":"2026011721383875700_ejhf1985-bib-0057","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026011721383875700_ejhf1985-bib-0058","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"2026011721383875700_ejhf1985-bib-0059","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"2026011721383875700_ejhf1985-bib-0060","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune checkpoint inhibitor-associated myocarditis","volume":"23","author":"Ganatra","year":"2018","journal-title":"Oncologist"},{"key":"2026011721383875700_ejhf1985-bib-0061","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0062","first-page":"190","article-title":"Immune checkpoint inhibitor therapy in patients with autoimmune disease","volume":"32","author":"Johnson","year":"2018","journal-title":"Oncology (Williston Park)"},{"key":"2026011721383875700_ejhf1985-bib-0063","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2026011721383875700_ejhf1985-bib-0064","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000498985","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: case series and review of the literature","volume":"12","author":"Agrawal","year":"2019","journal-title":"Case Rep Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0065","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur Heart J"},{"key":"2026011721383875700_ejhf1985-bib-0066","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","article-title":"Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Caforio","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011721383875700_ejhf1985-bib-0067","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"},{"key":"2026011721383875700_ejhf1985-bib-0068","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/clc.22634","article-title":"Short and long term radiation induced cardiovascular disease in patients with cancer","volume":"40","author":"Nielsen","year":"2017","journal-title":"Clin Cardiol"},{"key":"2026011721383875700_ejhf1985-bib-0069","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005633","article-title":"Long-term cardiovascular risk after radiotherapy in women with breast cancer","volume":"6","author":"Cheng","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026011721383875700_ejhf1985-bib-0070","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41416-018-0159-x","article-title":"Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer","volume":"119","author":"Boekel","year":"2018","journal-title":"Br J Cancer"},{"key":"2026011721383875700_ejhf1985-bib-0071","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ejhf.1620","article-title":"Heart failure after treatment for breast cancer","volume":"22","author":"Boekel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026011721383875700_ejhf1985-bib-0072","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11883-019-0810-x","article-title":"Effects of radiotherapy in coronary artery disease","volume":"21","author":"da Silva","year":"2019","journal-title":"Curr Atheroscler Rep"},{"key":"2026011721383875700_ejhf1985-bib-0073","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ejhf.1376","article-title":"The role of irradiated heart and left ventricular volumes in heart failure occurrence after childhood cancer","volume":"21","author":"Mansouri","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026011721383875700_ejhf1985-bib-0074","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2017.77.6351","article-title":"Cardiac structure injury after radiotherapy for breast cancer: cross-sectional study with individual patient data","volume":"36","author":"Taylor","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0075","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"2026011721383875700_ejhf1985-bib-0076","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1200\/JCO.2016.69.8480","article-title":"Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures","volume":"35","author":"van den Bogaard","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0077","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.radonc.2017.10.009","article-title":"Is the coronary artery calcium score associated with acute coronary events in breast cancer patients treated with radiotherapy?","volume":"126","author":"Roos","year":"2018","journal-title":"Radiother Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0078","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1053\/j.seminoncol.2019.01.006","article-title":"Treatment specific toxicities: hormones, antihormones, radiation therapy","volume":"46","author":"Plummer","year":"2019","journal-title":"Semin Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0079","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.radonc.2013.05.007","article-title":"Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach","volume":"107","author":"Langendijk","year":"2013","journal-title":"Radiother Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0080","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0081","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis","volume":"22","author":"Michel","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026011721383875700_ejhf1985-bib-0082","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/jpet.119.258178","article-title":"Pharmacology of ranolazine versus common cardiovascular drugs in patients with early diastolic dysfunction induced by anthracyclines or nonanthracycline chemotherapeutics: a phase 2b minitrial","volume":"370","author":"Minotti","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"2026011721383875700_ejhf1985-bib-0083","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","article-title":"Anthracycline-induced cardiotoxicity: a multicentre randomised trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society-one trial","volume":"94","author":"Cardinale","year":"2018","journal-title":"Eur J Cancer"},{"key":"2026011721383875700_ejhf1985-bib-0084","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006513","article-title":"Neurohormonal blockade and circulating cardiovascular biomarkers during anthracycline therapy in breast cancer patients: results from the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) study","volume":"6","author":"Gulati","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026011721383875700_ejhf1985-bib-0085","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026011721383875700_ejhf1985-bib-0086","doi-asserted-by":"crossref","DOI":"10.2196\/resprot.9906","article-title":"Early detection of cardiovascular changes after radiotherapy for breast cancer: protocol for a European multicenter prospective cohort study (MEDIRAD EARLY HEART Study)","volume":"7","author":"Walker","year":"2018","journal-title":"JMIR Res Protoc"},{"key":"2026011721383875700_ejhf1985-bib-0087","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","article-title":"Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy","volume":"61","author":"Thavendiranathan","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011721383875700_ejhf1985-bib-0088","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1200\/JCO.2009.26.7294","article-title":"Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging","volume":"28","author":"Walker","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0089","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1200\/JCO.2011.40.3584","article-title":"Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging","volume":"30","author":"Armstrong","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0090","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jcmg.2018.06.003","article-title":"Multi-modality imaging in the assessment of cardiovascular toxicity in the cancer patient","volume":"11","author":"Plana","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026011721383875700_ejhf1985-bib-0091","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis","volume":"4","author":"Oikonomou","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2026011721383875700_ejhf1985-bib-0092","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026011721383875700_ejhf1985-bib-0093","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ehjci\/jet159","article-title":"Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection","volume":"15","author":"Negishi","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026011721383875700_ejhf1985-bib-0094","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jcmg.2018.03.019","article-title":"Rationale and design of the strain surveillance of chemotherapy for improving cardiovascular outcomes: the SUCCOUR trial","volume":"11","author":"Negishi","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026011721383875700_ejhf1985-bib-0095","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/ejhf.1049","article-title":"Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience","volume":"20","author":"Fornaro","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026011721383875700_ejhf1985-bib-0096","doi-asserted-by":"crossref","first-page":"104577","DOI":"10.1016\/j.phrs.2019.104577","article-title":"Role of cardioprotective agents on chemotherapy-induced heart failure: a systematic review and network meta-analysis of randomized controlled trials","volume":"151","author":"Li","year":"2020","journal-title":"Pharmacol Res"},{"key":"2026011721383875700_ejhf1985-bib-0097","article-title":"Effects of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: a meta-analysis of randomized controlled trials","author":"Fang","year":"2020  3","journal-title":"Heart Fail Rev"},{"key":"2026011721383875700_ejhf1985-bib-0098","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10741-018-9755-3","article-title":"Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol","volume":"24","author":"Huang","year":"2019","journal-title":"Heart Fail Rev"},{"key":"2026011721383875700_ejhf1985-bib-0099","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/16078454.2020.1719726","article-title":"Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer","volume":"25","author":"Wang","year":"2020","journal-title":"Hematology"},{"key":"2026011721383875700_ejhf1985-bib-0100","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721383875700_ejhf1985-bib-0101","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","article-title":"2017 ACC\/AHA\/HFSA FOCUSED UPDATE of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"70","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026011721383875700_ejhf1985-bib-0102","first-page":"e13","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"2026011721383875700_ejhf1985-bib-0103","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2026011721383875700_ejhf1985-bib-0104","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"2026011721383875700_ejhf1985-bib-0105","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"2026011721383875700_ejhf1985-bib-0106","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"key":"2026011721383875700_ejhf1985-bib-0107","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"2026011721383875700_ejhf1985-bib-0108","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014","volume":"33","author":"Lyman","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0109","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0110","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026011721383875700_ejhf1985-bib-0111","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2\u2009x\u20092 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"2026011721383875700_ejhf1985-bib-0112","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/ehf2.12627","article-title":"Effectiveness of sacubitril-valsartan in cancer patients with heart failure","volume":"7","author":"Martin-Garcia","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026011721383875700_ejhf1985-bib-0113","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jaccao.2020.02.017","article-title":"Acute heart failure 29years after treatment for childhood cancer","volume":"2","author":"Camilli","year":"2020","journal-title":"JACC CardioOncol"},{"key":"2026011721383875700_ejhf1985-bib-0114","first-page":"147","article-title":"Cardiovascular drug interactions with tyrosine kinase inhibitors","volume":"13","author":"Haouala","year":"2010","journal-title":"Cardiovasc Med"},{"key":"2026011721383875700_ejhf1985-bib-0115","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/hon.2503","article-title":"Practical management of ibrutinib in the real life: focus on atrial fibrillation and bleeding","volume":"36","author":"Boriani","year":"2018","journal-title":"Hematol Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0116","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ejvs.2018.11.004","article-title":"A systematic review and meta-analysis of the efficacy and safety of anticoagulation in the treatment of venous thromboembolism in patients with cancer","volume":"57","author":"Kirkilesis","year":"2019","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2026011721383875700_ejhf1985-bib-0117","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213940","article-title":"Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: a systematic review and network meta-analysis","volume":"14","author":"Rossel","year":"2019","journal-title":"PLoS One"},{"key":"2026011721383875700_ejhf1985-bib-0118","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"2026011721383875700_ejhf1985-bib-0119","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1634\/theoncologist.2013-0239","article-title":"New oral anticoagulants and the cancer patient","volume":"19","author":"Short","year":"2014","journal-title":"Oncologist"},{"key":"2026011721383875700_ejhf1985-bib-0120","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/gerona\/59.3.M255","article-title":"Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care","volume":"59","author":"Fried","year":"2004","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2026011721383875700_ejhf1985-bib-0121","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/asheducation-2013.1.158","article-title":"Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers","volume":"2013","author":"Shanafelt","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2026011721383875700_ejhf1985-bib-0122","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s13670-015-0147-4","article-title":"The crossroads of geriatric cardiology and cardio-oncology","volume":"4","author":"Nguyen","year":"2015","journal-title":"Curr Geriatr Rep"},{"key":"2026011721383875700_ejhf1985-bib-0123","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.2011.39.9014","article-title":"Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum","volume":"30","author":"Jones","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0124","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/bmt.2013.58","article-title":"Cardiopulmonary fitness in patients undergoing hematopoietic SCT: a pilot study","volume":"48","author":"Wood","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2026011721383875700_ejhf1985-bib-0125","doi-asserted-by":"crossref","first-page":"e997","DOI":"10.1161\/CIR.0000000000000679","article-title":"Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association","volume":"139","author":"Gilchrist","year":"2019","journal-title":"Circulation"},{"key":"2026011721383875700_ejhf1985-bib-0126","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1634\/theoncologist.12-10-1156","article-title":"Cardiovascular reserve and risk profile of postmenopausal women after chemoendocrine therapy for hormone receptor-positive operable breast cancer","volume":"12","author":"Jones","year":"2007","journal-title":"Oncologist"},{"key":"2026011721383875700_ejhf1985-bib-0127","doi-asserted-by":"crossref","DOI":"10.1093\/ehjqcco\/qcaa015","article-title":"Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer","author":"Groarke","year":"2020  13","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026011721383875700_ejhf1985-bib-0128","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/0284186X.2013.781673","article-title":"Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial","volume":"53","author":"Hornsby","year":"2014","journal-title":"Acta Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0129","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1161\/CIRCULATIONAHA.117.024671","article-title":"Exercise therapy and cardiovascular toxicity in cancer","volume":"137","author":"Scott","year":"2018","journal-title":"Circulation"},{"key":"2026011721383875700_ejhf1985-bib-0130","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.cell.2019.10.024","article-title":"Multisystem toxicity in cancer: lessons from NASA\u2019s countermeasures program","volume":"179","author":"Scott","year":"2019","journal-title":"Cell"},{"key":"2026011721383875700_ejhf1985-bib-0131","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1200\/JCO.2015.65.6603","article-title":"Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer","volume":"34","author":"Jones","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0132","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jamaoncol.2018.2254","article-title":"Association of exercise with mortality in adult survivors of childhood cancer","volume":"4","author":"Scott","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0133","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nrclinonc.2012.27","article-title":"Exercise rehabilitation in patients with cancer","volume":"9","author":"Lakoski","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0134","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1200\/JCO.2017.77.5809","article-title":"Efficacy of exercise therapy on cardiorespiratory fitness in patients with cancer: a systematic review and meta-analysis","volume":"36","author":"Scott","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0135","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.jacc.2015.04.013","article-title":"Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St Jude Lifetime Cohort Study","volume":"65","author":"Armstrong","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026011721383875700_ejhf1985-bib-0136","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1161\/CIRCULATIONAHA.116.024811","article-title":"Population-based long-term cardiac-specific mortality among 34 489 five-year survivors of childhood cancer in Great Britain","volume":"135","author":"Fidler","year":"2017","journal-title":"Circulation"},{"key":"2026011721383875700_ejhf1985-bib-0137","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10654-018-0370-3","article-title":"The PanCareSurFup cohort of 83,333 five-year survivors of childhood cancer: a cohort from 12 European countries","volume":"33","author":"Grabow","year":"2018","journal-title":"Eur J Epidemiol"},{"key":"2026011721383875700_ejhf1985-bib-0138","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009122","article-title":"Risk and temporal changes of heart failure among 5-year childhood cancer survivors: a DCOG-LATER study","volume":"8","author":"Feijen","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026011721383875700_ejhf1985-bib-0139","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.2013.51.1055","article-title":"Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study","volume":"32","author":"Armstrong","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0140","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/S1470-2045(14)70409-7","article-title":"Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"16","author":"Armenian","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0141","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1634\/theoncologist.2015-0449","article-title":"Evaluating the utility of baseline cardiac function screening in early-stage breast cancer treatment","volume":"21","author":"Truong","year":"2016","journal-title":"Oncologist"},{"key":"2026011721383875700_ejhf1985-bib-0142","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaccao.2019.08.007","article-title":"The evolving design of NIH-funded cardio-oncology studies to address cancer treatment-related cardiovascular toxicity","volume":"1","author":"Minasian","year":"2019","journal-title":"JACC CardioOncol"},{"key":"2026011721383875700_ejhf1985-bib-0143","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1053\/j.seminoncol.2019.01.004","article-title":"Cardio-oncology in clinical studies and real life","volume":"46","author":"Dent","year":"2019","journal-title":"Semin Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0144","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1111\/bjh.16132","article-title":"Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia","volume":"187","author":"Marchesi","year":"2019","journal-title":"Br J Haematol"},{"key":"2026011721383875700_ejhf1985-bib-0145","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1200\/JCO.2008.21.1441","article-title":"Health behaviors, medical care, and interventions to promote healthy living in the Childhood Cancer Survivor Study cohort","volume":"27","author":"Nathan","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0146","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1200\/JCO.2008.16.9607","article-title":"Medical care in long-term survivors of childhood cancer: a report from the childhood cancer survivor study","volume":"26","author":"Nathan","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026011721383875700_ejhf1985-bib-0147","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jacbts.2017.12.007","article-title":"Increased afterload augments sunitinib-induced cardiotoxicity in an engineered cardiac microtissue model","volume":"3","author":"Truitt","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"2026011721383875700_ejhf1985-bib-0148","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.jacc.2018.07.028","article-title":"Accelerated left ventricular interstitial collagen deposition after receiving doxorubicin in hypertension","volume":"72","author":"Melendez","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026011721383875700_ejhf1985-bib-0149","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","article-title":"Cardio-oncology services: rationale, organization, and implementation","volume":"40","author":"Lancellotti","year":"2019","journal-title":"Eur Heart J"},{"key":"2026011721383875700_ejhf1985-bib-0150","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/ejhf.1292","article-title":"Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience","volume":"20","author":"Pareek","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026011721383875700_ejhf1985-bib-0151","article-title":"The EACVI survey on cardiac imaging in cardio-oncology","author":"Stankovic","year":"2020","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026011721383875700_ejhf1985-bib-0152","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/ehf2.12162","article-title":"Protocol update and preliminary results of EACVI\/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology","volume":"4","author":"Lancellotti","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026011721383875700_ejhf1985-bib-0153","author":"European Society of Cardiology"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.1985","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.1985","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/22\/12\/2290\/66111057\/eurjhf_22_12_2290.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/22\/12\/2290\/66111057\/eurjhf_22_12_2290.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:41:20Z","timestamp":1768704080000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/22\/12\/2290\/8384492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,2]]},"references-count":153,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,10,2]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.1985","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,10,2]]},"assertion":[{"value":"2020-07-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}